WALTHAM, Mass.--(BUSINESS WIRE)--Dec. 21, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a leading developer of biopharmaceutical compounds to treat cancer and certain ophthalmologic diseases, today announced that it completed a public offering of 7,475,000 shares of its common stock at a price of $3.65 per share. The underwriters have exercised in full their option to purchase 975,000 shares of OXiGENE’s common stock to cover over-allotments. OXiGENE’s gross proceeds from the offering, including the sale of over-allotment shares, were approximately $27,284,000. At completion of the offering, OXiGENE had approximately 28 million shares issued and outstanding.
